A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering from levodopa induced dyskinesias. - LID study

Merck Serono S.A. - Geneva0 个研究点目标入组 24 人开始时间: 2010年1月7日最近更新: 2013年3月4日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•The desired population to trial is advanced idiopathic PD patients treated with L-dopa and suffering from temporally predictable L-dopa induced peak-dose dyskinesia.
•For inclusion in the trial, all of the following inclusion criteria must be fulfilled:
•1. The subject has given his/her written informed consent to participate in the trial.
•2. The subject presents with a diagnosis of idiopathic Parkinson's disease according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria.
•3. The subject is an out-patient aged 30 years or above.
•4. PD subjects with a Hoehn and Yahr disease staging of II-IV (in the ON state).
•5. PD subjects experiencing levodopa induced dyskinesias, specifically predictable peak-dose dyskinesia.
•6. Peak-dose dyskinesia must be considered by the subject to be problematic and/or disabling.
•7. Peak-dose dyskinesia must warrant medical treatment in the Investigator’s opinion.
•8. The subject has participated successfully in a diary-card training session.
•9. In the judgment of the Investigator based on the subject’s history, previous treatments, and the clinical presentation, the subject is considered as being optimally treated at the present time (i.e., further adjustments of current medication are not expected to further improve the subject's symptoms of Parkinson's disease).
•10. Stable dose of all PD drugs for at least 4 weeks before Screening Visit. This may include: levodopa dopamine agonists, COMT inhibitors, and anticholinergics.
•11. The dose of levodopa and all PD drugs used during the trial must remain unchanged throughout the trial.
•12. Female subjects must be neither pregnant or breast-feeding and must lack child-bearing potential, as defined either by:
•- be either post menopausal for at least 2 years, surgically sterilised, or have undergone hysterectomy, or
•- if of child bearing potential, be willing to avoid pregnancy by using an adequate method of contraception for four weeks prior to, during and four weeks after the last dose of trial medication. For the purposes of this trial, women of childbearing potential are defined as all female subjects after puberty unless they are post-menopausal for at least two years, are surgically sterile or are sexually inactive.
•13. The subject shows adequate compliance with the schedule for intake of trial medication and the completion of the diaries.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Subjects are not eligible for this trial if they fulfil any of the following exclusion criteria:
•1. The subject has participated in any safinamide clinical trial before.
•2. The subject is experiencing exclusively diphasic, off state, myoclonic, dystonic, or akathetic dyskinesias without peak dose dyskinesia.
•3. (For female subjects) The subject is pregnant or lactating.
•4. Treatment with a MAO-B inhibitor within the eight weeks prior to the screening visit.
•5. Treatment with amantadine in the four weeks prior to the screening visit or budipine in the eight weeks prior to the screening visit.
•6. Treatment with opioids (e.g., tramadol, meperidine derivatives), SNRIs (e.g. venlafaxine, duloxetine), tri- or tetra-cyclic antidepressants, in the 8 weeks prior to the screening visit. Dextromethorphan will be permitted if used for treating cough.
•7. The subject has received neurosurgical intervention related to PD (e.g. deep brain stimulation, thalamotomy etc.) or is scheduled to do so during the trial period.
•8. Current clinically significant gastro-intestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease, including acute gastric ulcer, hypertension that is not well controlled, asthma, chronic obstructive pulmonary disease (COPD), and unstable Type I diabetes. Subjects with a history of gastric ulcer who have not had a recent episode of acute gastritis and are not currently experiencing gastric pain will be eligible for inclusion.
•9. Neoplastic disorder, which is either currently active or has been in remission for less than one year.
•10. Diagnosis of HIV, or positive test for Hepatitis C antibodies, or Hepatitis B surface antigen.
•11. Concomitant disease likely to interfere with trial medication (e.g. capable of altering absorption, metabolism, or elimination of the trial drug).
•12. The subject has any clinically significant illness that, in the Investigator’s opinion, might interfere with the subject's ability to participate in the trial.
•13. Second- or third-degree atrio-ventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, or a significant ECG abnormality, including QTc – 450 msec (males) or – 470 msec (females), where QTc is based on Bazett’s correction method.
•14. Ophthalmologic history including any of the following conditions: albino subjects, family history of hereditary retinal disease, progressive and/or severe diminution of visual acuity (i.e., 20/70), retinitis pigmentosa, retinal pigmentation due to any cause, any active retinopathy or ocular inflammation (uveitis), or diabetic retinopathy
•15. The subject is suffering from dementia or other severe neuropsychiatric illness that prevents him/her from giving informed consent, or has a total score on the MoCA <23 points.
•16. Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such.
•17. Known hypersensitivity to the trial treatment(s), including placebo or other comparator drug(s).
•18. The subject has legal incapacity or limited legal capacity.
•19. The subject is participating in another clinical trial or has done so within the past 30 days.
•20. Treatment with a drug that has hepatotoxic potential e.g., tamoxifen, within 4 weeks, or received radiation therapy or a drug with cytotoxic potential, e.g, chemotherapy, within 1 year prior to the screening v

研究者

发起方

Merck Serono S.A. - Geneva

相似试验

进行中（未招募）

不适用

A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of Type 2 diabetic patients with nonalcoholic steatohepatitis (NASH) - STRONG2Diabetic patients with Non-Alcoholic Steato-HepatitisMedDRA version: 9.1Level: LLTClassification code 10053219Term: Non-alcoholic steatohepatitis

EUCTR2007-003013-14-PTsanofi-aventis recherche & development720

进行中（未招募）

不适用

A trial to determine if safinamide can attenuate levodopa induced dyskinesia in Parkinson’s disease.Idiopathic Parkinson's diseaseMedDRA version: 14.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disorders

EUCTR2009-017174-20-ATMerck Serono S.A. - Geneva24

招募中

不适用

Clinical study to evaluate the efficacy of HUDC_VT in patients with bacterial vaginosisCertain infectious and parasitic diseases

KCT0002268Koera University Guro Hospital150

进行中（未招募）

不适用

A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)on diabetic patients with Non-Alcoholic Steato-HepatitisMedDRA version: 10.1Level: LLTClassification code 10053219Term: <Manually entered code. Term in E.1.1>

EUCTR2007-003012-61-HUsanofi recherche & developpement720

进行中（未招募）

不适用

EUCTR2007-003012-61-BEsanofi recherche & developpement720